This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This series is based on primary research data collected at one month, three months, and one year after commercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, the report assesses U.S. hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. The analysis provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other recently launched oncology drugs. 

Table of contents

  • Darzalex/Empliciti Launch Tracking Wave 3 (US)
    • Key Findings
      • Key Findings
    • Benchmarking Darzalex's and Empliciti's Launch Success vs. Other Launched Drugs
      • Usage Levels by Physicians Are Lower for Darzalex and Empliciti Than for Other Benchmark Drugs
    • Prescriber and Nonprescriber Profiles
      • Who Are the Darzalex and Empliciti Prescribers?
    • Darzalex and Empliciti Awareness and Perceptions
      • Unaided and Aided Awareness of Darzalex and Empliciti
      • Familiarity with Darzalex and Empliciti
        • Most Physicians Report High Levels of Familiarity with Darzalex and Empliciti
      • Sources of Familiarity with Darzalex and Empliciti
      • Initial Reaction to and Interest in Darzalex and Empliciti
        • Physicians Indicate Moderate to High Levels of Interest in Darzalex and Empliciti
      • Impressions of Darzalex and Empliciti
      • Prescriber and Nonprescriber Profiles
    • Darzalex and Empliciti Trial and Use
      • Willingness to Prescribe Darzalex and Empliciti
        • Willingness to Prescribe Darzalex and Empliciti Is High
      • Number of Patients Currently Receiving Darzalex and Empliciti
        • Darzalex and Empliciti Prescribed by High Proportion of Surveyed Physicians One-Year Postlaunch
      • Reasons for Not Yet Prescribing Darzalex and Empliciti
      • Anticipated Darzalex and Empliciti Use
      • Darzalex and Emplicti Performance on Key Attributes
        • Satisfaction Levels for Darzalex and Empliciti Remain High
    • Effectiveness of Face-to-Face Detailing for Darzalex and Empliciti
      • Darzalex and Empliciti Sales Representative Frequency and Reach
        • Slight Increase in Number of Physicians Visited by Darzalex and Empliciti Representatives at One-Year Postlaunch
      • Satisfaction with Darzalex and Empliciti Sales Representatives
        • Satisfaction with Darzalex and Empliciti Sales Representatives Is High
      • Darzalex and Empliciti Message Recall
        • Darzalex and Empliciti's Clinical Trial Data, and OS and PFS Data Were the Main Messages Communicated by Sales Representatives
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Abbreviations
      • Additional Information
        • Awareness of Drugs for Multiple Myeloma Treatment
        • Key Reasons for Choosing to Prescribe Another Agent Over Darzalex/Empliciti
        • Patient Inquiries and Requests Regarding Darzalex and Empliciti
        • Prescription Preference for Multiple Myeloma Patients
        • Coordination of Dosing Schedules to Minimize Waste
        • Requirements for Managed Care Approval of Darzalex and Empliciti
        • Influence of Managed Care Approval Process on Darzalex and Empliciti Prescriptions
        • Ease of Managed Care Process for Darzalex and Empliciti
        • Common Restrictions on the Duration of Treatment for Darzalex and Empliciti
        • Denial of Darzalex Prescriptions by Patients' Managed Care Plans
        • Case Study #1: Patient with Multiple Myeloma Previously Prescribed BD Regimen: Velcade + Dexamethasone
        • Case Study #2: Patient with Multiple Myeloma Quickly Progressed to Fourth Line of Therapy
        • Physician Willingness for Follow-Up Interviews

Author(s): Izabela Ammermann, PhD

Izabela Ammermann, , is a business insights analyst in the oncology division at Decision Resources Group. She is a specialist in multiple myeloma and pancreatic cancer and has expertise in chronic lymphocytic leukemia. Dr. Ammermann holds a in molecular biology from the Technical University of Munich and a in biotechnology from the Polish Academy of Sciences. Prior to joining Decision Resources Group, Dr. Ammermann worked as a postdoctoral research associate (Marie Curie research fellow) at Imperial College London. Dr. Ammermann has published several peer-reviewed papers.

Related Reports

Multiple Myeloma | Geographic Focus: China | Multiple Myeloma | China In-Depth | China

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the intro...

View Details

Multiple Myeloma | Landscape & Forecast | Disease Landscape & Forecast

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet...

View Details

Multiple Myeloma | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapi...

View Details

Multiple Myeloma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of mu...

View Details